metronidazole has been researched along with Diabetes Mellitus in 14 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to perform a 5-year follow-up analysis of a previously-published randomized trial (RCT) evaluating the 2-years effects of metronidazole (MTZ) plus amoxicillin (AMX) as adjuncts to scaling and root planing (SRP) in the treatment of periodontitis in type 2 diabetic patients." | 9.41 | Metronidazole and amoxicillin for patients with periodontitis and diabetes mellitus: 5-year secondary analysis of a randomized controlled trial. ( Cruz, DFD; da Silva, HDP; Duarte, PM; Feres, M; Figueiredo, LC; Miranda, TS; Retamal-Valdes, B, 2021) |
| "The aim of this study was to perform a 5-year follow-up analysis of a previously-published randomized trial (RCT) evaluating the 2-years effects of metronidazole (MTZ) plus amoxicillin (AMX) as adjuncts to scaling and root planing (SRP) in the treatment of periodontitis in type 2 diabetic patients." | 5.41 | Metronidazole and amoxicillin for patients with periodontitis and diabetes mellitus: 5-year secondary analysis of a randomized controlled trial. ( Cruz, DFD; da Silva, HDP; Duarte, PM; Feres, M; Figueiredo, LC; Miranda, TS; Retamal-Valdes, B, 2021) |
| " Ceftolozane/tazobactam is an antibacterial with potent activity against Gram-negative pathogens and is approved for the treatment of cIAI (with metronidazole) and cUTI (including pyelonephritis)." | 5.24 | Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam. ( Huntington, JA; Long, J; Popejoy, MW, 2017) |
| " The knowledge of adverse effects of antibiotics was greatest for tooth discoloration which is related to tetracycline." | 3.80 | Antibiotics prescription in Nigerian dental healthcare services. ( Azodo, CC; Ojehanon, PI, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (14.29) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Tucker, TR | 1 |
| Knitter, CA | 1 |
| Khoury, DM | 1 |
| Eshghi, S | 1 |
| Tran, S | 1 |
| Sharrock, AV | 1 |
| Wiles, TJ | 1 |
| Ackerley, DF | 1 |
| Mumm, JS | 1 |
| Parsons, MJ | 1 |
| Schattner, A | 1 |
| Uliel, L | 1 |
| Finn, T | 1 |
| Dubin, I | 1 |
| Cruz, DFD | 1 |
| Duarte, PM | 1 |
| Figueiredo, LC | 1 |
| da Silva, HDP | 1 |
| Retamal-Valdes, B | 1 |
| Feres, M | 1 |
| Miranda, TS | 1 |
| Popejoy, MW | 1 |
| Long, J | 1 |
| Huntington, JA | 1 |
| Souto, MLS | 1 |
| Rovai, ES | 1 |
| Ganhito, JA | 1 |
| Holzhausen, M | 1 |
| Chambrone, L | 1 |
| Pannuti, CM | 1 |
| Chen, HL | 1 |
| Bair, MJ | 1 |
| Lin, IT | 1 |
| Wu, CH | 1 |
| Lee, YK | 1 |
| Tormo-Badia, N | 1 |
| Håkansson, Å | 1 |
| Vasudevan, K | 1 |
| Molin, G | 1 |
| Ahrné, S | 1 |
| Cilio, CM | 1 |
| Azodo, CC | 1 |
| Ojehanon, PI | 1 |
| Lee, SU | 1 |
| Jung, IE | 1 |
| Kim, HJ | 1 |
| Kim, JS | 1 |
| TAYLOR, JA | 1 |
| PHILIPP, EE | 1 |
| Khalifa, M | 1 |
| Slim, I | 1 |
| Kaabia, N | 1 |
| Bahri, F | 1 |
| Trabelsi, A | 1 |
| Letaief, AO | 1 |
| Garavelli, PL | 1 |
| Sheehan, JP | 1 |
| Ulchaker, MM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Efficacy and Safety of Intravenous CXA-201 With That of Meropenem in Complicated Intraabdominal Infections[NCT01445678] | Phase 3 | 494 participants (Actual) | Interventional | 2011-12-23 | Completed | ||
| A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis[NCT01345929] | Phase 3 | 558 participants (Actual) | Interventional | 2011-06-20 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Clinical cure is complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure was required for the index infection. (NCT01445678)
Timeframe: TOC; 26-30 days after start of study drug administration
| Intervention | percentage of subjects (Number) |
|---|---|
| CXA-201 and Metronidazole as Treatment for cIAI | 83.0 |
| Meropenem as Treatment for cIAI | 87.3 |
Clinical response is complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure was required for the index infection. (NCT01445678)
Timeframe: EOT; Within 24 hours of last study drug administration
| Intervention | percentage of subjects (Number) |
|---|---|
| CXA-201 and Metronidazole as Treatment for cIAI | 89.2 |
| Meropenem as Treatment for cIAI | 92.3 |
Clinical response is complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure was required for the index infection. (NCT01445678)
Timeframe: EOT; Within 24 hours of last study drug administration
| Intervention | percentage of subjects (Number) |
|---|---|
| CXA-201 and Metronidazole as Treatment for cIAI | 97.1 |
| Meropenem as Treatment for cIAI | 97.5 |
Clinical response is clinical cure at TOC and no signs and symptoms recur or worsen since the TOC visit (NCT01445678)
Timeframe: LFU; 38 to 45 days after first study drug administration
| Intervention | percentage of subjects (Number) |
|---|---|
| CXA-201 and Metronidazole as Treatment for cIAI | 100 |
| Meropenem as Treatment for cIAI | 99.3 |
Clinical response is clinical cure at TOC and no signs and symptoms recur or worsen since the TOC visit. (NCT01445678)
Timeframe: LFU; 38 to 45 days after first study drug administration
| Intervention | percentage of subjects (Number) |
|---|---|
| CXA-201 and Metronidazole as Treatment for cIAI | 82.5 |
| Meropenem as Treatment for cIAI | 86.6 |
Success is eradication (absence of the baseline pathogen in a specimen appropriately obtained from the original site of infection) or presumed eradication (absence of material to culture in a subject who was assessed as a clinical cure) for each baseline pathogen (NCT01445678)
Timeframe: TOC; 26-30 days after start of study drug administration
| Intervention | percentage of subjects (Number) |
|---|---|
| CXA-201 and Metronidazole as Treatment for cIAI | 94.2 |
| Meropenem as Treatment for cIAI | 94.7 |
(NCT01345929)
Timeframe: Test of Cure Visit (7 Days [± 2 days] after completion of study drug administration)
| Intervention | percentage of subjects (Number) |
|---|---|
| CXA-201 as Treatment for cUTI | 76.9 |
| Levofloxacin as Treatment for cUTI | 68.4 |
(NCT01345929)
Timeframe: Test of Cure Visit (7 Days [± 2 days] after completion of study drug administration)
| Intervention | percentage of subjects (Number) |
|---|---|
| CXA-201 as Treatment for cUTI | 83.3 |
| Levofloxacin as Treatment for cUTI | 75.4 |
1 review available for metronidazole and Diabetes Mellitus
| Article | Year |
|---|---|
Efficacy of systemic antibiotics in nonsurgical periodontal therapy for diabetic subjects: a systematic review and meta-analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Dental Scaling; Diabetes Mellitus; Doxycycline; Drug Therapy, Co | 2018 |
2 trials available for metronidazole and Diabetes Mellitus
| Article | Year |
|---|---|
Metronidazole and amoxicillin for patients with periodontitis and diabetes mellitus: 5-year secondary analysis of a randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Dental Scaling; Diabetes Mellitus; Humans; Metronidazole; Period | 2021 |
Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Diabetes Complications; Di | 2017 |
Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Diabetes Complications; Di | 2017 |
Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Diabetes Complications; Di | 2017 |
Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Diabetes Complications; Di | 2017 |
11 other studies available for metronidazole and Diabetes Mellitus
| Article | Year |
|---|---|
An inducible model of chronic hyperglycemia.
Topics: Animals; Animals, Genetically Modified; Diabetes Mellitus; Hyperglycemia; Metronidazole; Nitroreduct | 2023 |
'Giant' pyogenic liver abscess and
Topics: Alcoholism; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ceftriaxone; Diabe | 2020 |
Clinical manifestations and risk factors of amebic liver abscess in Southeast Taiwan compared with other regions of Taiwan.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Alcoholics; Amebicides; Anti-Bacterial Agents; Diabe | 2013 |
Antibiotic treatment of pregnant non-obese diabetic mice leads to altered gut microbiota and intestinal immunological changes in the offspring.
Topics: Animals; Anti-Bacterial Agents; Biodiversity; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes | 2014 |
Antibiotics prescription in Nigerian dental healthcare services.
Topics: Acquired Immunodeficiency Syndrome; Amoxicillin; Anaphylaxis; Anti-Bacterial Agents; Antibiotic Prop | 2014 |
Metronidazole-induced combined peripheral and central vestibulopathy.
Topics: Aged; Anti-Infective Agents; Diabetes Mellitus; Diabetic Foot; Humans; Hypertension; Male; Metronida | 2016 |
METRONIDAZOLE--A NEW AGENT FOR COMBINED SOMATIC AND PSYCHIC THERAPY OF ALCOHOLISM. A CASE STUDY AND PRELIMINARY REPORT.
Topics: Alcoholism; Angina Pectoris; Diabetes Mellitus; Drug Therapy; Female; Hair; Humans; Metronidazole; N | 1964 |
VULVO-VAGINITIS.
Topics: Adolescent; Candidiasis, Vulvovaginal; Child; Diabetes Mellitus; Drug Therapy; Female; Gonorrhea; Hu | 1965 |
Regression of skin lesions of Kyrle's disease with metronidazole in a diabetic patient.
Topics: Adult; Anti-Infective Agents; Diabetes Mellitus; Humans; Keratosis; Male; Metronidazole; Treatment O | 2007 |
The therapy of blastocystosis.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Aged, 80 and over; Animals; Anti-Infect | 1991 |
Blastocystis hominis treatable cause of diabetic diarrhea.
Topics: Administration, Oral; Adult; Animals; Diabetes Complications; Diabetes Mellitus; Diagnosis, Differen | 1990 |